Janssen's sales of Darzalex exceed expectations
![Photo: Lars Møller / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13908748.ece/ALTERNATES/schema-16_9/doc7kh4jwevu893yhf88ud.jpg)
Sales of the Genmab-developed bone marrow cancer drug, Darzalex, which Johnson & Johnson has licensed, surpassed projections for the first quarter of 2022, as revealed by Johnson & Johnson’s financial report on Tuesday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab loses royalties case against Janssen
For subscribers
Genmab value drops by over USD 1.5bn after royalties defeat
For subscribers